CN101460480A - 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 - Google Patents

2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 Download PDF

Info

Publication number
CN101460480A
CN101460480A CNA2007800209481A CN200780020948A CN101460480A CN 101460480 A CN101460480 A CN 101460480A CN A2007800209481 A CNA2007800209481 A CN A2007800209481A CN 200780020948 A CN200780020948 A CN 200780020948A CN 101460480 A CN101460480 A CN 101460480A
Authority
CN
China
Prior art keywords
disease
alzheimer
dementia
dimethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800209481A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·伯格
约翰·赫德斯特罗姆
斯文·赫尔伯格
约翰·马尔姆伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
AstraZeneca AB
Original Assignee
Astex Therapeutics Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd, AstraZeneca AB filed Critical Astex Therapeutics Ltd
Publication of CN101460480A publication Critical patent/CN101460480A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800209481A 2006-04-05 2007-04-04 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 Pending CN101460480A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78954006P 2006-04-05 2006-04-05
US60/789,540 2006-04-05

Publications (1)

Publication Number Publication Date
CN101460480A true CN101460480A (zh) 2009-06-17

Family

ID=38563950

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800209481A Pending CN101460480A (zh) 2006-04-05 2007-04-04 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途

Country Status (5)

Country Link
US (1) US20090099217A1 (enExample)
EP (1) EP2004630A4 (enExample)
JP (1) JP2009532464A (enExample)
CN (1) CN101460480A (enExample)
WO (1) WO2007114771A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
CN102985412A (zh) * 2010-06-28 2013-03-20 詹森药业有限公司 可用于治疗阿尔茨海默病及其它形式的痴呆的3-氨基-5,6-二氢-1h-吡嗪-2-酮衍生物

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ES2306200T3 (es) 2004-07-28 2008-11-01 Schering Corporation Inhibidores macrociclicos de beta-secretasa.
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
KR20080028881A (ko) 2005-06-14 2008-04-02 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제, 이의제조방법 및 용도
WO2007049532A1 (ja) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
RU2476430C2 (ru) 2007-04-24 2013-02-27 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина, замещенные циклической группой
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2283016B1 (en) 2008-04-22 2014-09-24 Merck Sharp & Dohme Corp. Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
BRPI0915500A2 (pt) 2008-06-13 2019-08-27 Shionogi & Co derivado heterocíclico contendo enxofre tendo atividade inibitória de beta secretase
CA2736130C (en) 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
CN102272133A (zh) * 2008-11-06 2011-12-07 阿斯利康(瑞典)有限公司 淀粉样β的调节剂
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
AU2011263797B2 (en) 2010-06-09 2014-06-05 Janssen Pharmaceutica Nv 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
WO2012085038A1 (en) 2010-12-22 2012-06-28 Janssen Pharmaceutica Nv 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
CN103502231A (zh) 2011-01-21 2014-01-08 卫材R&D管理有限公司 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
HUE026338T2 (en) 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
MY163346A (en) 2011-03-09 2017-09-15 Janssen Pharmaceutica Nv 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (base)
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2703399A4 (en) 2011-04-26 2014-10-15 Shionogi & Co OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
USRE49873E1 (en) 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof
US9422277B2 (en) 2012-10-17 2016-08-23 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9416129B2 (en) 2012-10-17 2016-08-16 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
ES2769578T3 (es) 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
WO2014198851A1 (en) 2013-06-12 2014-12-18 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
WO2014198853A1 (en) 2013-06-12 2014-12-18 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
MX366063B (es) 2013-06-12 2019-06-26 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5-a]pira zina como inhibidores de beta-secretasa (bace).
JP2017538753A (ja) 2014-12-18 2017-12-28 ヤンセン ファーマシューティカ エヌ．ベー． ２，３，４，５−テトラヒドロピリジン−６−アミンおよび３，４−ジヒドロ−２Ｈ−ピロール−５−アミンの化合物のβセクレターゼ阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625026A (en) * 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
US20030114445A1 (en) * 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
US6777420B2 (en) * 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
CN101671307B (zh) * 2003-12-15 2014-05-14 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
CN101084198A (zh) * 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基－嘧啶酮及其用途
WO2006041404A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
MX2007016182A (es) * 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
EP1902057B1 (en) * 2005-06-14 2013-10-23 Merck Sharp & Dohme Corp. Macrocyclic heterocyclic aspartyl protease inhibitors
JP2009513656A (ja) * 2005-10-27 2009-04-02 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼインヒビター
PE20070798A1 (es) * 2005-10-31 2007-08-24 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
CN102985412A (zh) * 2010-06-28 2013-03-20 詹森药业有限公司 可用于治疗阿尔茨海默病及其它形式的痴呆的3-氨基-5,6-二氢-1h-吡嗪-2-酮衍生物

Also Published As

Publication number Publication date
EP2004630A1 (en) 2008-12-24
WO2007114771A1 (en) 2007-10-11
EP2004630A4 (en) 2010-05-19
US20090099217A1 (en) 2009-04-16
JP2009532464A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
CN101460480A (zh) 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
US7629356B2 (en) Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions
US20080161269A1 (en) Compounds 620
US7855213B2 (en) Compounds
US20080287460A1 (en) New compounds 835
US20090023762A1 (en) Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies
JP2009520685A (ja) 化合物およびそれらの使用ｉｖ
US20080214577A1 (en) New Compounds 320
JP2009515949A (ja) 新規な２−アミノピリミジノン誘導体およびそれらの使用
JP2009539973A (ja) アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
JP2009539975A (ja) アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
US20080051420A1 (en) New Compounds 317
WO2009005470A1 (en) Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005471A1 (en) Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2008063114A1 (en) Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
CN101360721A (zh) 新颖的2-氨基嘧啶酮衍生物或2-氨基吡啶酮衍生物及其用途
JP2009515950A (ja) 新規な２−アミノピリミジン誘導体およびその使用
CN101501040A (zh) 氨基-咪唑啉以及它们作为治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物的用途
HK1127036A (en) Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
HK1127034A (en) Novel 2-aminopyrimidine derivatives and their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090617